WHO added that the agreements mean that all 190 COVAX participants will have access to doses to protect vulnerable groups in the first half of 2021. And the group believes that by the end of 2021, at least 1.3 billion donor-funded doses will be available for 92 low-income economies, which target 20% of their population. He stressed that deliveries were based on regulatory approvals and the country`s willingness to receive vaccines. Ultimately, the program aims to provide 2 billion doses of safe and effective vaccines worldwide by the end of 2021. “This early interest is a huge vote of confidence in COVAX and our shared goal of protecting people around the world through the equitable allocation of a COVID-19 vaccine,” said Dr. Richard Hatchett, CEO of CEPI. “COVAX offers an innovative solution to the most serious public health crisis in living memory. It will accelerate the availability of safe and effective vaccines by rapidly investing in production capacity and maximize the chances of success by supporting a broad and diversified portfolio of vaccine candidates. With COVAX, by the end of 2021, we want to be able to vaccinate the lowest 20% of the population of all participating countries regardless of their income level. Ensuring equitable access is not just a matter of justice; This is the fastest way to end this pandemic” A coalition of 156 countries has agreed on a “Landmark” agreement to enable rapid and equitable global distribution of all new coronavirus vaccines to 3% of the population of participating countries, in order to protect vulnerable health systems, front-line medical security forces and front-line people in social institutions. “The COVID 19 pandemic, like any health crisis, offers us opportunities,” said Dr Soumya Swaminathan, WHO Chief Scientist. “An affordable and accessible vaccine will help us eliminate systemic health inequalities.
We need all the countries that support COVAX to achieve this goal and end the acute phase of the pandemic. COVAX`s partners have made significant progress to date, with seven of the nine CEPI-supported vaccine candidates already being conducted in the clinical trial course.